These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. [TRIAL STATISTICAL EVALUATION OF THE PREVENTIVE ACTION OF EPSILON-AMINOCAPROIC ACID ON THE HEMORRHAGIC COMPLICATIONS OF HEMOPHILIA]. POULAIN M; RENARD MJ; JOSSO F Hemostase; 1964; 4():307-9. PubMed ID: 14260674 [No Abstract] [Full Text] [Related]
64. The therapeutic role of epsilon-aminocaproic acid (EACA) for dental extractions in hemophiliacs. Walsh PN; Rizza CR; Evans BE; Aledort LM Ann N Y Acad Sci; 1975 Jan; 240():267-76. PubMed ID: 1078619 [TBL] [Abstract][Full Text] [Related]
66. [EPSILON-AMINOCAPROIC ACID AND FIBRINOLYSIS]. VAIREL E; LANDE M; LEGER L Presse Med (1893); 1964 Mar; 72():945-6. PubMed ID: 14119753 [No Abstract] [Full Text] [Related]
67. The onerous task of comparing treatments in inhibitor patients. Schulman S Thromb Haemost; 2007 Oct; 98(4):710-2. PubMed ID: 17938791 [No Abstract] [Full Text] [Related]
70. [FIBRINOLYSIS; APPLICATION IN THE CLINIC (EPSILON-AMINOCAPROIC ACID)]. MOERS AM; BOSMAN GA Folia Med Neerl; 1964 Dec; 7():175-8. PubMed ID: 14265805 [No Abstract] [Full Text] [Related]
71. Cryoprecipitate in the management of haemophilia in Kenya. Taylor JR; Ahluwalia NS; Morrison CJ; Kaviti JN; Cardwell CL East Afr Med J; 1969 Feb; 46(2):121-8. PubMed ID: 5798053 [No Abstract] [Full Text] [Related]
73. [OBSERVATIONS ON ACTIVATION OF FIBRINOLYSIS IN HEMORRHAGES DUE TO TONSILLECTOMY AND ON CAUSAL TREATMENT WITH EPSILON-AMINOCAPROIC ACID]. GHILARDI F; VOENA G; BUSCA G Ann Laringol Otol Rinol Faringol; 1965; 64():55-63. PubMed ID: 14295928 [No Abstract] [Full Text] [Related]
74. Primary amyloidosis and myelomatosis associated with excessive fibrinolytic acitivty. Millard LG; Rowell NR Br J Dermatol; 1976 May; 94(5):569-71. PubMed ID: 1268067 [TBL] [Abstract][Full Text] [Related]
75. On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients. Mikovic D; Woodhams BJ; Holmström M; Elezovic I; Antovic A; Mobarrez F; Elfvinge P; Antovic JP Int J Lab Hematol; 2012 Feb; 34(1):35-40. PubMed ID: 21707936 [TBL] [Abstract][Full Text] [Related]
76. Effect of ethamsylate and aminocaproic acid on menstrual blood loss in women using intrauterine devices. Kasonde JM; Bonnar J Br Med J; 1975 Oct; 4(5987):21-2. PubMed ID: 1174906 [No Abstract] [Full Text] [Related]
77. Antihaemophilic cryoprecipitate from fresh plasma and its use in haemophilia. Brüster H; Glassner K; Riech PC Ger Med Mon; 1968 Mar; 13(3):129-33. PubMed ID: 5656869 [No Abstract] [Full Text] [Related]
78. [Effect of epsilon-aminocaproic acid on the sexual cycle]. Okuyama M Horumon To Rinsho; 1966 Nov; 14(11):919-22. PubMed ID: 5342175 [No Abstract] [Full Text] [Related]
79. [COMPARATIVE STUDY ON THE EFFECT OF EPSILON-AMINOCAPROIC ACID, ACETYL-EPSILON-AMINOCAPROIC ACID AND CAPROLACTAM FOR VARIOUS PARAMETERS OF THE FIBRINOLYTIC SYSTEM]. AUERSWALD W; DOLESCHEL W Wien Med Wochenschr; 1965 Feb; 115():102-5. PubMed ID: 14260441 [No Abstract] [Full Text] [Related]
80. Future pharmacological strategies in management of Haemophilia. Sørensen B Thromb Res; 2010 Oct; 126(4):259-61. PubMed ID: 20153023 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]